Clinical Trial Update: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating gemtuzumab ozogamicin in combination with chemotherapy to assess minimal residual disease levels in adults with untreated, de novo acut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: RECRUITING